James DeYonker

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) shares have been on a tear and are trading near a two-year high after speculation started doing the rounds that its pain treatment candidate DSUVIA is poised to get early approval. About 3.25 million shares exchanged hands, roughly 2.5 times the average...